ABI-2280 / Antiva Biosci - LARVOL DELTA

THE ACYCLIC NUCLEOSIDE PHOSPHONATE ABI-2280 IS A NOVEL INHIBITOR OF HPV DNA PRODUCTIVE AMPLIFICATION (IPVC 2025) - "ABI-2280 efficiently inhibits HPV-18 DNA amplification and triggers cellular DNA damage predominantly in the differentiated strata. The inhibitory effects of ABI-2280 exposure on HPV-18-infected raft cultures are superior to and differ from those of cidofovir (cdv) at 15μM and can be clearly separated from effects on normal, uninfected raft cultures. At nanomolar levels, ABI-2280 is a promising anti-HPV therapeutic."

Late-breaking abstract • Infectious Disease • Vaginal Cancer

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts (clinicaltrials.gov) - P1/2 | N=160 | Recruiting | Sponsor: Antiva Biosciences | Trial primary completion date: May 2025 ➔ Oct 2025

Trial primary completion date • Human Papillomavirus Infection • Infectious Disease • Oncology

A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov) - P1/2 | N=110 | Recruiting | Sponsor: Antiva Biosciences | N=29 ➔ 110 | Trial completion date: May 2024 ➔ Jun 2025 | Trial primary completion date: Apr 2024 ➔ Jun 2025

Enrollment change • Trial completion date • Trial primary completion date • Gynecology • Oncology • CDKN2A

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts (clinicaltrials.gov) - P1/2 | N=160 | Recruiting | Sponsor: Antiva Biosciences | Trial completion date: Aug 2025 ➔ Feb 2026

Trial completion date • Human Papillomavirus Infection • Infectious Disease • Oncology

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts (clinicaltrials.gov) - P1/2 | N=160 | Recruiting | Sponsor: Antiva Biosciences

New P1/2 trial • Human Papillomavirus Infection • Infectious Disease • Oncology

A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov) - P1/2 | N=29 | Recruiting | Sponsor: Antiva Biosciences | Trial completion date: Aug 2023 ➔ May 2024 | Trial primary completion date: Jul 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Gynecology • Oncology • CDKN2A

Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO (PRNewswire) - "Antiva Biosciences...announced the closing of a $53 million Series E equity financing....Proceeds from the financing, which will fund the company into late 2025, will support the advancement of the company's lead development candidate, ABI-2280, into key efficacy studies following completion of its ongoing Phase 1 trials. Planned studies include a Phase 2 clinical trial in high-grade cervical intraepithelial neoplasia (CIN 2,3) and an exploratory study as a potential treatment for high-risk HPV infection, specifically in subtypes that can lead to cancer."

Financing • Oncology

A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov) - P1/2 | N=29 | Recruiting | Sponsor: Antiva Biosciences | Not yet recruiting ➔ Recruiting

Enrollment open • Gynecology • Oncology • CDKN2A

A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov) - P1/2 | N=29 | Not yet recruiting | Sponsor: Antiva Biosciences

New P1/2 trial • Gynecology • Oncology • CDKN2A